RAC1 and melanoma: Concerning treatment, in vitro studies have shown that melanoma cell lines harboring the RAC1 P29S mutation are resistant to BRAF and MEK inhibitors, but its role in conferring this resistance is still to be elucidated (Watson et al., 2014).